Staphefekt (Psoriasis)

Staphefekt™, developed by Micreos, is the world’s first bacteria-killing enzymes (known as endolysins) available for human use on intact skin. Staphefekt™ specifically targets the bacteria Staphylococcus aureus, including strains that are resistant to antibiotics such as MRSA. Endolysins originate from bacteriophages (phages), the natural enemy of bacteria. Both have been around for billions of years. The Staphefekt endolysin exhibits two additional useful characteristics to combat bacterial infections: rapid killing of bacteria and very limited likelihood of emerging resistance.

Level of evidence: C

HelloSkin’s experts were unable to find any clinical trials investigating the effect of Staphefekt in people with psoriasis.

The human skin flora contains billions of bacteria, the vast majority protects our skin and are needed for maintaining a healthy skin balance. Disruption of this balance due to weakened immune system or skin damage can thereby lead to severe and aggravated skin conditions like psoriasis1.

Staphefekt SA.100 is an endolysin, an antibacterial enzyme specifically targeting Staphylococcus aureus. Contrary to antibiotics, Staphefekt kills only S. aureus, leaving the beneficial bacteria like S. epidermis intact. By targeting essential parts of the cell wall of S. aureus, resistance is neither observed nor expected in the future use of Staphefekt. As an active ingredient in moisturizers, Staphefekt is therefore suitable for long-term daily use as suppression therapy of S. aureus on the skin.

Some of the well-known symptoms caused by psoriasis are dry skin and itching, which often lead to great discomfort. Furthermore, these two symptoms can result in decreased skin barrier function and thereby infectional lesions. The causal relationship between colonization with S. aureus and lesional inflammations still has to be clarified, but recent studies suggest that S. aureus colonization is the primary cause, rather than only secondary of skin damage or an insufficient antistaphylococcal immune status2.

Even though no clinical studies on Staphefekt have been performed in patients suffering from psoriasis, trials of Staphefekt’s effect on S. aureus in atopic dermatitis patients have been showing promising effect. The study showed a 60% reduction of both MRRS and MRSA resistant strains of S. Aureus within 60 minutes after incubating with 30 microgram/mL Staphefekt SA.100. Furthermore, none of the 4 control bacteria naturally found on healthy skin were affected by Staphefekt, thereby displaying its specificity towards S. aureus3.

The concentration of an ingredient is important for its efficacy, and therefore products containing the same ingredient may not necessarily have the same effect as in the studies mentioned above.

Updated: July 2017

References

1J Am Acad Dermatol. 2009

2Genome Res. 2012

3http://www.micreos.com